Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CARA |
---|---|---|
09:32 ET | 2917 | 0.649 |
09:36 ET | 148 | 0.6496 |
09:38 ET | 1100 | 0.6496 |
09:45 ET | 2140 | 0.6488 |
09:48 ET | 308 | 0.643886 |
09:52 ET | 500 | 0.637049 |
09:56 ET | 600 | 0.64 |
09:57 ET | 620 | 0.63202 |
09:59 ET | 100 | 0.6397 |
10:03 ET | 100 | 0.6336 |
10:06 ET | 200 | 0.6396 |
10:08 ET | 100 | 0.6366 |
10:14 ET | 1300 | 0.6448 |
10:28 ET | 630 | 0.6446 |
10:30 ET | 100 | 0.6447 |
10:33 ET | 111 | 0.6447 |
10:37 ET | 1270 | 0.6434 |
10:39 ET | 200 | 0.6434 |
10:42 ET | 2778 | 0.6449 |
10:44 ET | 2825 | 0.6448 |
10:46 ET | 100 | 0.654 |
10:50 ET | 9047 | 0.642567 |
10:57 ET | 200 | 0.6545 |
11:04 ET | 2000 | 0.6472 |
11:06 ET | 100 | 0.6545 |
11:08 ET | 775 | 0.6472 |
11:11 ET | 200 | 0.6545 |
11:13 ET | 100 | 0.6587 |
11:15 ET | 100 | 0.6492 |
11:18 ET | 491 | 0.6584 |
11:20 ET | 164 | 0.64 |
11:24 ET | 100 | 0.6584 |
11:27 ET | 998 | 0.6584 |
11:29 ET | 621 | 0.6492 |
11:31 ET | 600 | 0.655548 |
11:33 ET | 100 | 0.658 |
11:36 ET | 600 | 0.6584 |
11:38 ET | 110 | 0.6405 |
11:40 ET | 1100 | 0.6575 |
11:42 ET | 100 | 0.6575 |
11:45 ET | 300 | 0.6575 |
11:49 ET | 100 | 0.6565 |
11:54 ET | 1100 | 0.64 |
11:56 ET | 100 | 0.6499 |
11:58 ET | 172 | 0.64 |
12:02 ET | 100 | 0.6499 |
12:03 ET | 134 | 0.640495 |
12:07 ET | 600 | 0.64 |
12:09 ET | 151 | 0.6401 |
12:12 ET | 10916 | 0.6499 |
12:18 ET | 200 | 0.6499 |
12:21 ET | 100 | 0.6499 |
12:25 ET | 325 | 0.6499 |
12:30 ET | 600 | 0.6499 |
12:32 ET | 243 | 0.65 |
12:34 ET | 100 | 0.6499 |
12:36 ET | 1356 | 0.6499 |
12:38 ET | 100 | 0.6499 |
12:39 ET | 400 | 0.6401 |
12:41 ET | 100 | 0.6498 |
12:48 ET | 300 | 0.6499 |
12:50 ET | 199 | 0.6499 |
12:57 ET | 100 | 0.6497 |
12:59 ET | 2571 | 0.6497 |
01:01 ET | 200 | 0.6497 |
01:03 ET | 1912 | 0.6492 |
01:06 ET | 300 | 0.64 |
01:08 ET | 200 | 0.64 |
01:10 ET | 100 | 0.648167 |
01:14 ET | 200 | 0.649 |
01:17 ET | 600 | 0.6495 |
01:19 ET | 200 | 0.6495 |
01:21 ET | 400 | 0.6495 |
01:24 ET | 100 | 0.6495 |
01:35 ET | 300 | 0.6471 |
01:39 ET | 300 | 0.6476 |
01:42 ET | 100 | 0.6499 |
01:44 ET | 100 | 0.6499 |
01:48 ET | 300 | 0.64495 |
01:53 ET | 100 | 0.6499 |
02:02 ET | 267 | 0.6499 |
02:08 ET | 268 | 0.644951 |
02:09 ET | 100 | 0.6499 |
02:18 ET | 100 | 0.6449 |
02:22 ET | 400 | 0.6471 |
02:24 ET | 11514 | 0.636 |
02:26 ET | 300 | 0.6359 |
02:29 ET | 358 | 0.6345 |
02:33 ET | 2300 | 0.6363 |
02:38 ET | 1762 | 0.637 |
02:40 ET | 3000 | 0.6391 |
02:42 ET | 100 | 0.63615 |
02:47 ET | 100 | 0.63615 |
02:49 ET | 300 | 0.63615 |
02:54 ET | 1100 | 0.63615 |
02:58 ET | 300 | 0.6391 |
03:00 ET | 300 | 0.6391 |
03:07 ET | 139 | 0.6391 |
03:12 ET | 790 | 0.6391 |
03:14 ET | 200 | 0.648049 |
03:16 ET | 5997 | 0.6476 |
03:18 ET | 200 | 0.6499 |
03:20 ET | 140 | 0.6476 |
03:21 ET | 130 | 0.6476 |
03:23 ET | 854 | 0.6499 |
03:25 ET | 400 | 0.6499 |
03:30 ET | 1060 | 0.6499 |
03:34 ET | 644 | 0.649 |
03:36 ET | 416 | 0.6497 |
03:38 ET | 560 | 0.6499 |
03:41 ET | 640 | 0.64995 |
03:43 ET | 9022 | 0.65645 |
03:45 ET | 3322 | 0.6564 |
03:48 ET | 6376 | 0.6593 |
03:50 ET | 200 | 0.6593 |
03:52 ET | 900 | 0.6597 |
03:54 ET | 9021 | 0.67 |
03:56 ET | 32155 | 0.6623 |
03:57 ET | 1000 | 0.6623 |
03:59 ET | 32053 | 0.6728 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cara Therapeutics Inc | 38.0M | -0.3x | --- |
ImmuCell Corp | 35.3M | -8.5x | --- |
Aadi Bioscience Inc | 43.7M | -0.7x | --- |
Turnstone Biologics Corp | 66.6M | -0.8x | --- |
SQZ Biotechnologies Co | 884.7K | 0.0x | --- |
Prenetics Global Ltd | 74.5M | -1.2x | --- |
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $35.1M |
---|---|
Revenue (TTM) | $16.9M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-2.26 |
Book Value | $1.05 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -729.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.